Portfolio companies news

  • 13 November 2017

    Clearside Biomedicals Phase 1/2 Open Label Clinical Trial of CLS-TA With and Without Eylea in Diabetic Macular Edema Presented at the American Academy of Ophthalmology 2017 Annual Meeting

    Clearside Biomedicals Phase 1/2 Open Label Clinical Trial of CLS-TA With and Without Eylea in Diabetic Macular Edema Presented at the American Academy of Ophthalmology 2017 Annual Meeting

    Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced that, on Friday, November 10, 2017, during the Retina Subspecialty Day of the American Academy of Ophthalmology  2017 Annual Meeting in New Orleans Charles C. Wykoff presented preliminary results from an exploratory clinical trial of CLS-TA, Clearside’s proprietary suspension formulation of the corticosteroid triamcinolone acetonide for suprachoroidal administration with and without intravitreally injected EYLEA® (aflibercept) for the treatment of diabetic macular edema.

  • 08 November 2017

    Clearside Biomedical, Inc. Announces Third Quarter 2017 Financial Results and Provides Corporate Update

    Clearside Biomedical, Inc. Announces Third Quarter 2017 Financial Results and Provides Corporate Update

    Clearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today reported financial results for the quarter and nine months ended  September 30, 2017  and provided an update on its key development programs.

  • 08 November 2017

    Neothetics Provides Business Update and Reports Third Quarter 2017 Financial Results

    Neothetics Provides Business Update and Reports Third Quarter 2017 Financial Results

    Neothetics , Inc. (NASDAQ:NEOT) provided a business update and reported financial results for the third quarter 2017. Research and development expenses for the third quarter of 2017 were approximately  $0.5 million , compared to  $1.0 million  for the same quarter in 2016. Research and development expenses for the nine months ended  September 30, 2017  were  $3.6 million , compared to  $5.7 million  for the same period in 2016. 

  • 07 November 2017

    Syndax Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Clinical and Business Update

    Syndax Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Clinical and Business Update

    Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced that it has agreed to sell 2,021,018 shares of its common stock to Biotechnology Value Fund, L.P. and certain of its affiliates ("BVF") in a registered direct offering.  

  • 02 November 2017

    Epic Sciences Launches Single-Cell Microsatellite and Chromosomal Instability Genomic Analysis

    Epic Sciences Launches Single-Cell Microsatellite and Chromosomal Instability Genomic Analysis

    Epic Sciences, Inc. adds simultaneous microsatellite instability (MSI) and chromosomal instability (CIN) measurements, also known as genomic scarring analysis, to the single cell next generation sequencing (NGS) workflow for clinical research of immuno-oncology therapies. MSI is currently utilized to identify patients who may respond to PD-1 checkpoint inhibitors across multiple cancer indications. 

  • 31 October 2017

    Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2017 Financial Results

    Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2017 Financial Results

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the "Company"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update and reported its financial results for the quarter ended September 30, 2017.

  • 24 October 2017

    Clearside Biomedical Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CLS-TA Used Together with Eylea in Patients with Diabetic Macular Edema

    Clearside Biomedical Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CLS-TA Used Together with Eylea in Patients with Diabetic Macular Edema

    Clearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced completion of patient enrollment in the Phase 2 clinical trial (“TYBEE”) of CLS-TA, Clearside’s proprietary suspension formulation of the corticosteroid triamcinolone acetonide for suprachoroidal administration (“suprachoroidal CLS-TA”), used together with intravitreally administered EYLEA® (aflibercept) (“intravitreal Eylea”) for the treatment of diabetic macular edema (“DME”).  Patient follow-up in the TYBEE trial is 6 months. 

  • 17 October 2017

    Syndax Announces $25 Million Registered Direct Offering of Common Stock

    Syndax Announces $25 Million Registered Direct Offering of Common Stock

    Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced that it has agreed to sell 2,021,018 shares of its common stock to Biotechnology Value Fund, L.P. and certain of its affiliates ("BVF") in a registered direct offering.  

  • 17 October 2017

    Syndax Expands Pipeline with Exclusive Worldwide License to Allergan's Portfolio of Menin-MLL Inhibitors

    Syndax Expands Pipeline with Exclusive Worldwide License to Allergan's Portfolio of Menin-MLL Inhibitors

    Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced that it has entered into an exclusive worldwide license agreement with Vitae Pharmaceuticals, Inc., a subsidiary of Allergan plc, for a portfolio of preclinical, orally-available small molecule inhibitors of the interaction of Menin with the Mixed Lineage Leukemia ("MLL") protein. These compounds have potential application in the treatment of a genetically-defined subset of acute leukemias with chromosomal rearrangements in the MLL gene ("MLL-r"). Syndax expects to initiate clinical studies in 2019.

  • 17 October 2017

    Neothetics, Inc. and Evofem Biosciences, Inc. Announce Merger Agreement to Create Womens Health Company

    Neothetics, Inc. and Evofem Biosciences, Inc. Announce Merger Agreement to Create Womens Health Company

    Neothetics, Inc. (NASDAQ: NEOT) and Evofem Biosciences, Inc. today announced they have entered into a definitive agreement under which privately-held Evofem Biosciences will merge with a wholly-owned subsidiary of Neothetics in an all-stock transaction. The merger will position the combined company with an opportunity to become a leading women’s health company that develops and commercializes novel products. Upon closing of the transaction, Neothetics will be renamed Evofem Biosciences, Inc., and will be under the leadership of Evofem Biosciences’ Chief Executive Officer, Saundra Pelletier.

All Portfolio

MEDIA CENTER

  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

All news